Anal cancer in Sweden 2015–2019. Implementation of guidelines, structural changes, national registry and early results

References

• Rao S, Guren MG, Khan K, et al. Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up⋆. Ann Oncol. ESMO Guidelines Committee. Electronic address: [email protected] 2021;32(9):1087–1100.
   PubMed Web of Science ®Google Scholar
• Leon O, Guren M, Hagberg O, et al. Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to nordic guidelines. Radiother Oncol. 2014;13(3):352–358.
   Web of Science ®Google Scholar
• Bentzen AG, Balteskard L, Wanderås EH, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta Oncologica (Stockholm, Sweden). 2013;52(4):736–744.
   PubMed Web of Science ®Google Scholar
• R Core Team. A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. URL. https://www.R-project.org/.2020.
   Google Scholar
• Rygalski CJ, Zhao S, Eskander A, et al. Time to surgery and survival in head and neck cancer. Ann Surg Oncol. 2021;28(2):877–885.
   PubMed Web of Science ®Google Scholar
• Harris JP, Chen MM, Orosco RK, et al. Association of survival with shorter time to radiation therapy after surgery for US patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2018;144(4):349–359.
   PubMed Web of Science ®Google Scholar
• Sekhar H, Zwahlen M, Trelle S, et al. Nodal stage migration and prognosis in anal cancer: a systematic review, Meta-regression, and simulation study. The Lancet Oncology. 2017; 18(10):1348–1359.
   PubMed Web of Science ®Google Scholar
• Guren MG, Sebag-Montefiore D, Franco P, et al. Treatment of squamous cell carcinoma of the anus, unresolved areas and future perspectives for research: Perspectives of research needs in anal cancer. Clin Colorectal Cancer. 2021;20(4):279–287.
   PubMed Web of Science ®Google Scholar
• Guren MG, Aagnes B, Nygård M, et al. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer. 2019;18(1):e96–e103.
   PubMed Web of Science ®Google Scholar
• James RD, Glynne-Jones R, Meadows HM, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. Lancet Oncol. 2013;14(6):516–524.
   PubMed Web of Science ®Google Scholar
• Graf R, Wust P, Hildebrandt B, et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology. 2003;65(1):14–22.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Sebag-Montefiore D, Meadows HM, et al. Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. Lancet Oncol. ACT II study group 2017;18(3):347–356.
   PubMed Web of Science ®Google Scholar
• Peiffert D, Tournier-Rangeard L, Gerard JP, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. J Clin Oncol. 2012; 30(16):1941–1948.
   PubMed Web of Science ®Google Scholar
• Jones M, Hruby G, Solomon M, et al. The role of FDG-PET in the initial staging and response assessment of anal cancer: a systematic review and Meta-analysis. Ann Surg Oncol. 2015;22(11):3574–3581.
   PubMed Web of Science ®Google Scholar
• Kochhar R, Renehan AG, Mullan D, et al. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. Eur Radiol. 2017;27(2):607–617.
   PubMed Web of Science ®Google Scholar
• Ajani JA, Winter KA, Gunderson LL, et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA. 2008;299(16):1914–1921.
   PubMed Web of Science ®Google Scholar
• Holliday EB, Lester SC, Harmsen WS, et al. Extended-Field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the Para-Aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2018;102(1):102–108.
   PubMed Web of Science ®Google Scholar
• Eng C, Chang GJ, You YN, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5(22):11133–11142.
   PubMedGoogle Scholar
• Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with american joint committee on cancer stages I to III carcinoma of the anal canal. J Clin Oncol. 2014;32(17):1812–1817.
   PubMed Web of Science ®Google Scholar
• Moberger P, Sköldberg F, Birgisson H. Evaluation of the swedish colorectal cancer registry: an overview of completeness, timeliness, comparability and validity. Acta Oncol. 2018;57(12):1611–1621.
   PubMed Web of Science ®Google Scholar